Hematologic Malignancy
Primary Systemic Amyloidosis
CI-CAN-00009108Explore in graph →
HematologicNon-malignant
- NCIt
- C8299
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00009108Explore in graph →
Clinical trials
19 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01728259 | First-line Pomalidomide, Bortezomib, and Dexamethasone For AL Amyloidosis or LCDD | terminated | Phase 1 | 18 | Barbara Ann Karmanos Cancer InstituteOTHER | 2 | May 9, 2023 | clinicaltrials |
| NCT00006251 | Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine, Mycophenolate Mofetil, Donor Lymphocyte Infusion in Treating Patients With Hematopoietic Cancer | completed | Phase 1 / Phase 2 | 21 | Fred Hutchinson Cancer CenterOTHER | 2 | Jan 21, 2020 | clinicaltrials |
| NCT00890747 | Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy | completed | Phase 1 | 42 | National Cancer Institute (NCI)NIH | 1 | Mar 17, 2014 | clinicaltrials |
| NCT00025415 |
Data updated 22 days agoSource updated May 9, 2023source: clinicaltrials
| Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction |
| completed |
| Phase 1 |
| 60 |
| National Cancer Institute (NCI)NIH |
| 1 |
| Feb 7, 2013 |
| clinicaltrials |
| NCT00030381 | Iododoxorubicin in Treating Patients With Primary Systemic Amyloidosis | terminated | Phase 1 | 22 | National Cancer Institute (NCI)NIH | 1 | Jan 16, 2013 | clinicaltrials |